secwatch.observer — SEC 8-K summary
======================================

Issuer:     Actinium Pharmaceuticals, Inc. (ATNM)
CIK:        0001388320
Form:       8-K
Filed at:   2026-08-14T21:00:38+00:00
Accession:  0001213900-26-090232
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Actinium gets NYSE plan acceptance through Nov 2027; adds Actimab-A patents and manufacturing
--------------------------------------------------------------------------------

- NYSE Regulation accepted compliance plan; listing extended through Nov 27, 2027, maximum period under Section 1009.
- Three US patents issued for Actimab-A: US 12,491,274 (sarcoma), US 12,539,340 (solid tumors), US 12,410,249 (low blast AML).
- Canadian applications for venetoclax combo and CLAG-M combo advanced to pre-grant/allowed status.
- Added second manufacturer under IND; will supply NCI CRADA and company studies with milestones from H2 2026.
- Company remains non-compliant with Sections 1003(a)(ii) and (iii); delisting risk if plan not met by Nov 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1388320/000121390026090232/0001213900-26-090232-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1388320/000121390026090232/ea0301890-8k_actinium.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-090232

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer